Research programme: neuraminidase inhibitors - AllaChem/ASAVI/ChemDiv

Drug Profile

Research programme: neuraminidase inhibitors - AllaChem/ASAVI/ChemDiv

Alternative Names: AV 5027; AV 5075C; AV 5080; Influenza virus neuraminidase inhibitors - AllaChem/ASAVI/ChemDiv

Latest Information Update: 14 Nov 2013

Price : $50

At a glance

  • Originator ChemDiv
  • Developer AllaChem; ChemDiv
  • Class Acids; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 14 Nov 2013 Preclinical trials in Influenza virus infections in USA (PO) before Nov 2013
  • 14 Nov 2013 Preclinical trials in Influenza virus infections in Russia (PO) before Nov 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top